Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.

ABSTRACT:

Background

Incomplete attack remission is the main cause of disability in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Apheresis therapies such as plasma exchange and immunoadsorption are widely used in neuroimmunology. Data on apheresis outcomes in MOGAD attacks remain limited.

Methods

We retrospectively evaluated all apheresis treated attacks occurring in patients with MOGAD between 2008 and 2023 at 18 Neuromyelitis Optica Study Group centres. Treatment response was categorised as complete, partial or no remission. Preattack and follow-up Expanded Disability Status Scale (EDSS) and visual Functional System Scores (FSS) were used to calculate absolute outcomes (ΔEDSS/Δvisual FSS). Predictors of complete remission were analysed using a generalised

SUBMITTER: Schwake C 

PROVIDER: S-EPMC12322437 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature